Please assess the completion status of the following clinical trial:

Trial Title: A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Healthy volunteers:~1. Male or female between 18 and 65 years old with a BMI of 18-32kg/m2~2. Must be in good health and not have any health condition which could interfere with the absorption, distribution or elimination of study drug, or with the clinical and laboratory assessments in this study~CHB patients:~1. Male or female between 18 and 65 years of age, with a BMI of 18-35kg/m2 and a minimum body weight of 45 kg~2. Must have chronic hepatitis B with no history of clinical decompensation~3. Seropositive for HIV, HCV, or HDV antibody at Screen~4. Previous treatment with any HBV antiviral treatments within the last 3 months~5. Other known cause of liver disease, including NASH

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- ABI-H0731 or Matching Placebo (Type: EXPERIMENTAL): ABI-H0731 in varying doses of tablets by mouth for 1 day, 7 days, or 28 days
- ABI-H0731 or Placebo and ETV or TDF (Type: EXPERIMENTAL): ABI-H0731 and entecavir or tenofovir in combination in a yet to be determined dose by mouth for 28 days
- ABI-H0731 or Placebo and a Nucleos(t)ide and Pegasys (Type: EXPERIMENTAL): ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).